Tyrosine kinase inhibitors: From rational design to clinical trials

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Medicinal research reviews (Print)

• Publication date

  2001-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/med.1022PMID 11607931
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis

  2004cited by this paper
• Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells.

  2000cited by this paper
• New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.

  2000cited by this paper
• Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.

  2000cited by this paper
• Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

  2000cited by this paper
• PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

  2000influential reference
• Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.

  2000cited by this paper
• Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.

  2000cited by this paper
• Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.

  2000cited by this paper
• New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis

  2000cited by this paper
• SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.

  1999cited by this paper
• Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones.

  1999cited by this paper
• In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor.

  1999cited by this paper
• The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases.

  1999cited by this paper
• Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.

  1999cited by this paper
• Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials.

  1998cited by this paper
• Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases.

  1998cited by this paper
• Tyrosine Kinase Inhibitors. 14. Structure−Activity Relationships for Methyl- amino-Substituted Derivatives of 4-[(3-Bromophenyl)amino]-6-(methylamino)- pyrido[3,4-d]pyrimidine (PD 158780), a Potent and Specific Inhibitor of the Tyrosine Kinase Activity of Receptors for the EGF Family of Growth Facto

  1998cited by this paper
• Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.

  1998cited by this paper
• 1‐Oxo‐3‐aryl‐1H‐indene‐2‐carboxylic Acid Derivatives as Selective Inhibitors of Fibroblast Growth Factor Receptor‐1 Tyrosine Kinase.

  1998cited by this paper
• Current progress towards the development of tyrosine kinase inhibitors as anticancer agents

  1998cited by this paper
• Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors.

  1998cited by this paper
• Protein kinase inhibitors: structural determinants for target specificity.

  1998cited by this paper
• Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR–ABL tyrosine kinase, CGP 57148

  1998cited by this paper
• Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).

  1998influential reference
• Tyrosine kinase inhibitors in cancer treatment (Part II)

  1998cited by this paper
• Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives

  1997cited by this paper
• Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.

  1997cited by this paper
• Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.

  1997cited by this paper
• CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins.

  1997influential reference
• Small molecule inhibitors of the platelet-derived growth factor receptor, the fibroblast growth factor receptor, and Src family tyrosine kinases.

  1997cited by this paper
• The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells.

  1997cited by this paper
• Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor.

  1997cited by this paper
• Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials.

  1997cited by this paper
• Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

  1997cited by this paper
• ZD1839, AN EPIDERMAL GROWTH FACTOR TYROSINE KINASE INHIBITOR SELECTED FOR CLINICAL DEVELOPMENT

  1997cited by this paper
• 1-Oxo-3-aryl-1H-indene-2-carboxylic acid derivatives as selective inhibitors of fibroblast growth factor receptor-1 tyrosine kinase

  1997cited by this paper
• The role of vascular endothelial growth factor in blood vessel formation.

  1996cited by this paper
• Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.

  1996influential reference
• Phenylamino‐Pyrimidine (PAP) Derivatives: A New Class of Potent and Selective Inhibitors of Protein Kinase C (PKC)

  1996cited by this paper
• Phenylamino-pyrimidine (PAP) — derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors

  1996cited by this paper
• 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.

  1996cited by this paper
• Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

  1996influential reference
• Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor.

  1996cited by this paper
• Modelling study of protein kinase inhibitors: Binding mode of staurosporine and origin of the selectivity of CGP 52411

  1995cited by this paper
• Vascular endothelial growth factor.

  1993cited by this paper
• Abl tyrosine kinase in signal transduction and cell-cycle regulation.

  1993cited by this paper
• Cancer: Principles and Practice of Oncology

  1982cited by this paper
• Cancer : Principles and Practice of Oncology

  1982cited by this paper
• [Chronic leukemias].

  1973cited by this paper

• Perioperative Management of Targeted and Immunologic Agents in Neurosurgical Oncology.

  2026cites this paper
• RTK_RAG: Leveraging Retrieval Augmented Generation with Multi-Window Convolutional Neural Networks for Superior ATP Binding Site Prediction in Receptor Tyrosine Kinases

  2025cites this paper
• Glivec to generic imatinib switch: in vitro comparative dissolution assessment, bioequivalence, safety, and tolerability of 400 mg imatinib tablets in healthy volunteers

  2025cites this paper
• Insights into Halogen-Induced Changes in 4-Anilinoquinazoline EGFR Inhibitors: A Computational Spectroscopic Study

  2024cites this paper
• GraphEGFR: Multi‐task and transfer learning based on molecular graph attention mechanism and fingerprints improving inhibitor bioactivity prediction for EGFR family proteins on data scarcity

  2024cites this paper
• Synthesis of novel triazole-urea hybrids and their antiproliferative activity against pancreatic cancer through suppression of eEF2K and induction of apoptosis

  2024cites this paper
• Design, synthesis, molecular docking, and evaluation of sulfonyl quinazoline analogues as promising liver cancer drugs.

  2024cites this paper
• The pathogenesis and development of targeted drugs in acute T lymphoblastic leukaemia

  2023influential citation
• Insights into the recent progress in the medicinal chemistry of pyranopyrimidine analogs.

  2022cites this paper
• Role of tyrosine kinase inhibitor in chronic myeloid leukemia patients with SARS-CoV-2 infection: A narrative Review

  2022cites this paper
• Design, microwave assisted synthesis, and molecular modeling study of some new 1,3,4-thiadiazole derivatives as potent anticancer agents and potential VEGFR-2 inhibitors.

  2021cites this paper
• Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors.

  2021cites this paper
• Cardiotoxicity of Antineoplastic Therapies and Applications of Induced Pluripotent Stem Cell-Derived Cardiomyocytes

  2021cites this paper
• Three‐component reaction for synthesis of 2‐amino ‐6‐aryl‐5‐(phenylamino)‐3, 7‐dihydro‐4 H ‐pyrrolo[2,3‐ d ]pyrimidin‐4‐one derivatives in water

  2020cites this paper
• Design, synthesis, and anticancer activity of novel 4-thiazolidinone-phenylaminopyrimidine hybrids

  2020cites this paper
• Synthesis, Molecular Docking, and DFT Calculation of a Half‐Strapped BODIPY as Potential EGFR Inhibitor**

  2020cites this paper
• Thiopyrimidine‐5‐carbonitrile Derivatives as VEGFR‐2 Inhibitors: Synthesis, Anticancer Evaluation, Molecular Docking, ADME Predictions and QSAR Studies

  2020cites this paper
• Dual targeting of TAM receptors Tyro3, Axl, and MerTK: Role in tumors and the tumor immune microenvironment

  2020cites this paper
• Nilotinib alters the efflux transporter-mediated pharmacokinetics of afatinib in mice.

  2019cites this paper
• Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis

  2019cites this paper
• Synthesis, anticancer activity, toxicity evaluation and molecular docking studies of novel phenylaminopyrimidine - (thio)urea hybrids as potential kinase inhibitors

  2019cites this paper
• Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell

  2019cites this paper
• Progress in research on protein tyrosine kinase inhibitors

  2019cites this paper
• Identifying the reactive metabolites of tyrosine kinase inhibitors in a comprehensive approach: Implications for drug‐drug interactions and hepatotoxicity

  2019cites this paper
• Decarboxylative cross-couplings of 2-aminopyrimidine-5-carboxylic acids

  2018cites this paper
• Treatment strategies to reverse efflux transporter-mediated resistance to Tyrosine kinase inhibitors

  2018influential citation
• Kinase-targeted cancer therapies: progress, challenges and future directions

  2018cites this paper
• Discovery of Melanocortin Ligands via a Double Simultaneous Substitution Strategy Based on the Ac-His-dPhe-Arg-Trp-NH2 Template.

  2018cites this paper
• A review of the challenge in measuring and standardizing BCR-ABL1

  2017cites this paper
• Combination Immunotherapy for Type 1 Diabetes

  2017cites this paper
• Repertoire by Delivering Differential Signals IgH Chains and Tunes the Pre-B Cell Pre-B Cell Receptor Assesses the Quality of

  2017cites this paper
• The Synthesis of Peptide-Based Macrocycles by Huisgen Cycloaddition

  2017cites this paper
• Genomic Profiling of Chronic Myelogenous Leukemia: Basic and Clinical Approach

  2017cites this paper
• Investigating the Applications of Electroporation Therapy for Targeted Treatment of Glioblastoma Multiforme Based on Malignant Properties of Cells

  2017cites this paper
• 2D QSAR and Virtual Screening based on Pyridopyrimidine Analogs of Epidermal Growth Factor Receptor Tyrosine Kinase.

  2016cites this paper
• Synthesis and cytotoxic evaluation of novel indenoisoquinoline-substituted triazole hybrids.

  2016cites this paper
• Neuronal NTPDase3 Mediates Extracellular ATP Degradation in Trigeminal Nociceptive Pathway

  2016cites this paper
• Design and Synthesis of Novel Schiff Base-Benzothiazole Hybrids as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors.

  2016cites this paper
• Preventing interpersonal violence in Panama: is a parenting intervention developed in Australia culturally appropriate?

  2016cites this paper
• Indole-based, Antiproliferative Agents Targeting Tubulin Polymerization.

  2016cites this paper
• Dehydrosulfurative C-N Cross-Coupling and Concomitant Oxidative Dehydrogenation for One-Step Synthesis of 2-Aryl(alkyl)aminopyrimidines from 3,4-Dihydropyrimidin-1H-2-thiones.

  2016cites this paper
• Anti-Inflammatory Activity

  2016cites this paper
• Privileged scaffolds in lead generation

  2015cites this paper
• Protein Kinases in the Era of Precision Medicine

  2015cites this paper
• Targets in anticancer research--A review.

  2015cites this paper
• Oncologic Treatment of Pediatric Brainstem Tumors

  2015cites this paper
• Cabozantinib reverses multidrug resistance of human hepatoma HepG2/adr cells by modulating the function of P‐glycoprotein

  2015cites this paper
• Design, synthesis and anticancer activity of furochromone and benzofuran derivatives targeting VEGFR-2 tyrosine kinase

  2015cites this paper
• Ten things you should know about protein kinases: IUPHAR Review 14

  2015influential citation
• Multifactorial Diseases and the Challenges in the Design of Multi­target Drugs: The Contribution of the Laboratory of Evaluation and Synthesis of Bioactive Substances - LASSBio®

  2015cites this paper
• Recent developments on thiourea based anticancer chemotherapeutics.

  2015cites this paper
• Studies for development of novel quinazolinones: new biomarker for EGFR.

  2015cites this paper
• An integrated flow and microwave approach to a broad spectrum protein kinase inhibitor

  2015cites this paper
• Prevalence of KRAS mutations in metastatic colorectal cancer: A retrospective observational study from India.

  2014cites this paper
• Advances in Neuroimmunology: From Bench to Bedside

  2014cites this paper
• Design, synthesis and anticancer activity of benzofuran derivatives targeting VEGFR-2 tyrosine kinase

  2014cites this paper
• Chemical Constituents from the Heartwood of Haematoxylon campechianum as Protein Tyrosine Kinase Inhibitors

  2014cites this paper
• Synthesis of fused pyrrolo[3,4-d]tetrahydropyrimidine derivatives by proline-catalyzed multicomponent reaction

  2014cites this paper
• Systems biology brings new dimensions for structure-based drug design.

  2014cites this paper
• Studies on the inhibitory models of pyrazoline derivatives as EGFR kinase inhibitors by 3D-QSAR and molecular docking

  2014cites this paper
• Chitosan: an efficient promoter for the synthesis of 2-aminopyrimidine-5-carbonitrile derivatives in solvent free conditions

  2014cites this paper
• Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

  2014cites this paper
• Apoptotic effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine osteosarcoma cells

  2013cites this paper
• NPTEL WEB COURSE – ADVANCED CLINICAL PROTEOMICS

  2013cites this paper
• Novel 5-anilinoquinazoline-8-nitro derivatives as inhibitors of VEGFR-2 tyrosine kinase: synthesis, biological evaluation and molecular docking.

  2013cites this paper
• An Update in the Use of Antibodies to Treat Glioblastoma Multiforme

  2013cites this paper
• Knockdown of β-catenin with Dicer-Substrate siRNAs Reduces Liver Tumor Burden In vivo

  2013cites this paper
• Synthesis, biological evaluation and docking studies of new pyrrolo[2,3-d] pyrimidine derivatives as Src family-selective tyrosine kinase inhibitors

  2013cites this paper
• inhibitor Inhibition of acute lymphoblastic and myeloid leukemias by a novel kinase

  2013cites this paper
• Antitumor activity of liposomal formulations of Bis-naphthalimide derivatives and Erlotinib: in vitro study in pancreatic cancer cell lines Dissertation of the Master Degree in Pharmaceutical Technology

  2013cites this paper
• Three-component assembly of structurally diverse 2-aminopyrimidine-5-carbonitriles.

  2013cites this paper
• Unraveling hidden regulatory sites in structurally homologous metalloproteases.

  2013cites this paper
• Kinase Inhibitors in Cancer

  2013cites this paper
• One-pot synthesis of bis(amino)-1,2,4-thiadiazoles via direct SNAr

  2013cites this paper
• TYPES OF DNA DAMAGE

  2013cites this paper
• Complementary Fe(3+)- and Ti(4+)-immobilized metal ion affinity chromatography for purification of acidic and basic phosphopeptides.

  2012cites this paper
• The Development and Use of Genetically Tractable Preclinical Mouse Models

  2012cites this paper
• Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer

  2012cites this paper
• Synthesis and structure-activity relationships of (aryloxy)quinazoline ureas as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.

  2012cites this paper
• Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents.

  2012cites this paper
• Synthesis and Antileukemic Activity of Novel 2‐(4‐(2,4‐dimethoxybenzoyl)phenoxy)‐1‐(4‐(3‐(piperidin‐4‐yl)propyl)piperidin‐1‐yl)ethanone Derivatives

  2012cites this paper
• P 11 Pyridine caffeic acid benzyl ester ( CABE ) analogues target the ATP pocket of atypical RIO kinases

  2012cites this paper
• Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies.

  2012cites this paper
• Design and synthesis of 2(1H)-pyrazinones as inhibitors of protein kinases

  2012cites this paper
• Antitumor activity of HM781‐36B, a highly effective pan‐HER inhibitor in erlotinib‐resistant NSCLC and other EGFR‐dependent cancer models

  2012cites this paper
• The effect of monoclonal antibody cetuximab (C225) in combination with tyrosine kinase inhibitor gefitinib (ZD1839) on colon cancer cell lines

  2012cites this paper
• Targeting cancer with small-molecular-weight kinase inhibitors.

  2012cites this paper
• Human Cancer Biology Activated MET Is a Molecular Prognosticator and Potential Therapeutic Target for Malignant Peripheral Nerve Sheath Tumors

  2011cites this paper
• Kinase Inhibitors in Signal Transduction Therapy

  2011cites this paper
• Strategies of multi-objective optimization in drug discovery and development

  2011cites this paper
• Efficient three-step one-pot synthesis of a novel 2,3,5-substituted pyrazine library.

  2011cites this paper
• Molecular determinants of therapeutic response to targeted therapies in metastatic colorectal cancer

  2011cites this paper
• Proteomic investigation of the MDM2 interactome and linear motif interactions

  2011cites this paper
• Acenaphtho[1,2-b]pyrrole-based selective fibroblast growth factor receptors 1 (FGFR1) inhibitors: design, synthesis, and biological activity.

  2011cites this paper
• Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy

  2011cites this paper
• Design, Synthesis and Characterization of a Highly Effective Inhibitor for Analog-Sensitive (as) Kinases

  2011cites this paper
• Synthesis and in vitro EGFR (ErbB1) tyrosine kinase inhibitory activity of 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines.

  2011cites this paper
• Drug discovery and the use of computational approaches for infectious diseases.

  2011cites this paper
• Dose study of the multikinase inhibitor , LY 2457546 , in patients with relapsed acute myeloid leukemia to assess safety , pharmacokinetics , and pharmacodynamics

  2011cites this paper
• [4-(6,7-Disubstituted quinazolin-4-ylamino)phenyl] carbamic acid esters: a novel series of dual EGFR/VEGFR-2 tyrosine kinase inhibitors

  2011cites this paper